玻璃体腔注射雷珠单抗联合视网膜光凝治疗糖尿病性黄斑水肿的效果

摘要
图/表
参考文献(18)
相关文章 (10)

全文: PDF (0 KB) HTML (41 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨玻璃体腔注射雷珠单抗联合视网膜光凝治疗糖尿病性黄斑水肿的效果。方法回顾性分析2017年1月～2018年1月在我院确诊的90 例（91 眼）糖尿病性黄斑水肿患者的临床资料，根据不同的治疗方式，将其分为治疗组（45 例，46 眼）和对照组（45 例，45 眼）。治疗组患者采用玻璃体腔注射雷珠单抗联合黄斑格栅样光凝或局灶光凝治疗，对照组患者采用雷珠单抗单独治疗。比较两组患者治疗后1、3 个月的最佳矫正视力、治疗前后黄斑中心凹区域视网膜厚度、黄斑水肿渗漏及不良反应发生情况。结果治疗组患者治疗后3 个月的最佳矫正视力优于对照组，差异有统计学意义（P＜0.05）；两组患者治疗后1 个月的最佳矫正视力比较，差异无统计学意义（P＞0.05）。两组患者治疗后1、3 个月的黄斑中心凹区域视网膜厚度低于治疗前，差异有统计学意义（P＜0.05）；治疗组患者治疗后1、3 个月的黄斑中心凹区域视网膜厚度低于对照组，差异有统计学意义（P＜0.05）。对照组患者治疗后3 个月的黄斑中心凹区域视网膜厚度高于本组治疗后1 个月，差异有统计学意义（P＜0.05）。治疗后3 个月复查眼底血管造影，治疗组患者的渗漏眼占比低于对照组，差异有统计学意义（P＜0.05）。治疗随访期间，两组患者均无眼部和全身不良反应。结论与玻璃体腔注射雷珠单抗单独治疗相比，雷珠单抗联合视网膜光凝治疗糖尿病性黄斑水肿在改善视力、恢复视网膜功能方面效果更佳，且具有良好的安全性。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：糖尿病性黄斑水肿, 雷珠单抗, 玻璃体腔注射, 视网膜激光光凝

Abstract：Objective To explore the effect of intravitreal injection of Ranibizumab combined with retinal photocoagulation in the treatment of diabetic macular edema. Methods A retrospective analysis was conducted on the clinical data of 90 patients (91 eyes) with diabetic macular edema diagnosed in our hospital from January 2017 to January 2018. According to different treatment methods, they were divided into the treatment group (45 cases, 46 eyes) and the control group (45 cases, 45 eyes). The patients in the treatment group were given intravitreal injection of Ranibizumab combined with macular grid photocoagulation or focal photocoagulation, and the patients in the control group were given Ranibizumab single treatment. The best corrected visual acuity at 1 month and 3 months after treatment, the retinal thickness at macula central fovea before and after treatment, the macular edema and leakage, and the occurrence of adverse reactions were compared. Results The best corrected visual acuity at 3 months after treatment in the treatment group was better than that in the control group, with statistically significant difference (P＜0.05). There was no statistically significant difference in the best corrected visual acuity at 1 month after treatment between the two groups (P＞0.05). The retinal thickness at macula central fovea in the two groups at 1 month and 3 months after treatment was lower than that before treatment, with statistically significant difference (P＜0.05). The retinal thickness at macula central fovea in the treatment group at 1 month and 3 months after treatment was lower than that in the control group, with statistically significant difference (P＜0.05). The retinal thickness at macula central fovea in the control group at 3 months after treatment was higher than that in the control group at 1 month after treatment, with statistically significant difference (P＜0.05). The fundus fluorescein angiography was repeated at 3 months after treatment, and the proportion of leakage eyes in the treatment was lower than that in the control group, with statistically significant difference (P＜0.05). During the treatment follow-up, there were no adverse reactions in eyes or whole body in the two groups. Conclusion In comparison with intravitreal injection of Ranibizumab single treatment, intravitreal injection of Ranibizumab combined with retinal photocoagulation has better effect in improving visual acuity and restoring retinal function in patients with diabetic macular edema, with better safety.

Key words： Diabetic macular edema Ranibizumab Intravitreal injection Retinal photocoagulation

收稿日期: 2020-03-20

作者简介: 张丹（1985-），女，四川雅安人，硕士，主治医师，主要从事眼科临床工作

引用本文:

张丹；王皎皎. 玻璃体腔注射雷珠单抗联合视网膜光凝治疗糖尿病性黄斑水肿的效果[J]. 中国当代医药, 2020, 27(29): 12-16.
ZHANG Dan WANG Jiao-jiao. Effect of intravitreal injection of Ranibizumab combined with retinal photocoagulation in the treatment of diabetic macular edema. 中国当代医药, 2020, 27(29): 12-16.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2020/V27/I29/12

[6]	Wilkinson CP，Ferris FL，Klein RE，et al.Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales[J].Ophthalmology，2003，110（9）：1677-1682.
[7]	杨晓璐，邹海东，许迅，等.糖尿病黄斑水肿患病率调查及相关因素分析[J].上海交通大学学报（医学版），2012，32（2）：160-167.
[8]	雷祥，范珂，崔红培，等.不同类型视网膜病变患者视网膜外层厚度变化研究[J].眼科新进展，2019，39（6）：536-539.
[9]	王相宁，李淑婷，杜新华，等.不同光相干断层扫描分型糖尿病黄斑水肿患眼玻璃体腔注射雷珠单抗与激光光凝治疗后视力观察[J].中华眼底病杂志，2017，33（2）：134-138.
[10]	赵洋，石岩.糖尿病黄斑水肿发病机制和治疗进展[J].医学综述，2019，25（17）：3463-3472.
[11]	Deschler EK，Sun JK，Silva PS.Side-effects and complications of laser treatment in diabetic retinal disease[J].Semin Ophthalmol，2014，29（5-6）：290-300.
[12]	刘凌，刘勇，阴正勤.雷珠单抗联合光凝治疗糖尿病视网膜病变黄斑水肿[J].局解手术学杂志，2015，17（3）：260-263.
[13]	陈凯，周洪伟.激光光凝联合雷珠单抗治疗糖尿病性黄斑水肿[J].国际眼科杂志，2019，19（9）：1598-1601.
[14]	韩崧，刘敬花.玻璃体腔注射雷珠单抗联合视网膜激光光凝术治疗视网膜分支静脉阻塞继发黄斑水肿的效果观察[J].北京医学，2017，39（4）：347-350.
[16]	李琰，邵玲，杜敏，等.雷珠单抗联合激光光凝治疗糖尿病性黄斑水肿的疗效[J].国际眼科杂志，2018，18（8）：1454-1456.
[17]	陶荣三，陈梦平，荆文涛.中西医结合治疗糖尿病性黄斑水肿临床研究[J].中医学报，2017，14（9）：45-48.
[18]	黄建冬，宋振宇.黄斑区格栅样光凝单独或联合雷珠单抗治疗糖尿病性黄斑水肿[J].国际眼科杂志，2016，16（3）：493-495.
[15]	Bressler NM，Varma R，Mitchell P，et al.Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema：Report From RESTORE，RIDE，and RISE Trials[J].JAMA Ophthalmol，2016，134（2）：160-166.
[1]	许迅，卢一.重视对糖尿病黄斑水肿的诊治[J].中华眼底病杂志，2018，34（4）：313-316.
[2]	Ansari WH，Han MM，Haq S，et al.Baseline Ocular Characteristics of Patients Undergoing Initiation of Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema[J].Ophthalmic Surg Lasers Imaging Retina，2019，50（2）：69-75.
[3]	王露露，孙艳红，韦企平，等.糖尿病视网膜病变激光治疗的并发症及其防治[J].国际眼科杂志，2019，19（3）：405-408.
[4]	Brito P，Costa J，Gomes N，et al.Serological inflammatory factors as biomarkers for anatomic response in diabetic macular edema treated with anti-VEGF[J].J Diabetes Comp lications，2018，32（7）：643-649.
[5]	Cai S，Yang Q，Li X，et al.The efficacy and safety of aflibercept and conbercept in diabetic macular edema[J].Drug Des Devel Ther，2018，12：3471-3483.